RNAimmune is a leading company in the field of messenger RNA (mRNA) technology with more than 20 years' expertise in handling and optimizing this versatile molecule for medical purposes. The principle of RNAimmune's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/24/20 | $2,350,000 | Seed |
Terra Magnum Capital Partners | undisclosed |
